PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 47/36, A61P 35/00

A1

(11) International Publication Number: WO 00/41730

(43) International Publication Date: 20 July 2000 (20.07.00)

(21) International Application Number: PCT/AU00/00004

(22) International Filing Date: 6 January 2000 (06.01.00)

(30) Priority Data:

PP 8131	13 January 1999 (13.01.99)	AU
PQ 3938	9 November 1999 (09.11.99)	AU

(71) Applicant *(for all designated States except US)*: MEDITECH RESEARCH LIMITED [AU/AU]; Level 1, Sterling House, 8 Parliament Place, West Perth, W.A. 6005 (AU).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: BROWN, Tracey [AU/AU]; Department of Molecular Biology And Biochemistry, Monash University, Clayton, VIC 3168 (AU).

(74) Agent: GRIFFITH HACK; Level 3, 509 St Kilda Road, Melbourne, VIC 3004 (AU).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: A COMPOSITION AND METHOD FOR THE ENHANCEMENT OF THE EFFICACY OF DRUGS

(57) Abstract

The present invention relates to the enhancement of the efficacy of drugs, and more particularly, with overcoming the resistance of cells or organisms to drugs. In particular, the present invention provides a method for enhancing the effectiveness of a cytotoxic or anti-neoplastic agent, comprising the step of co-administering said agent with hyaluronan, wherein co-administration with hyaluronan enhances the agent's cancer cell-killing potential.